Status:

COMPLETED

Capsule Endoscopy for HEmorrhage in the ER

Lead Sponsor:

George Washington University

Collaborating Sponsors:

Medtronic

Conditions:

Upper Gastrointestinal Bleeding

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This is a multi-center randomized controlled trial examining the use of Video Capsule Endoscopy (VCE) to discharge low-moderate risk patients with suspected upper gastrointestinal bleeds (UGIB) from t...

Detailed Description

Video capsule endoscopy (VCE) was initially approved in 2001 by the Food and Drug Administration. VCE offers potential advantages over traditional EGD including the ability to be performed 24 hours a ...

Eligibility Criteria

Inclusion

  • 1\. Individuals aged ≥ 18 years presenting to the Emergency Department with likely upper GI bleed (bloody emesis and/or coffee ground vomiting and/or melena) that has occurred within the previous 48 hours.

Exclusion

  • Upper GI Bleed with hemodynamic instability (BP\<90 mmHg, pulse\>120 beats per minute, and Hgb \< 9 g/dL)
  • High Risk Upper GI Bleed (Glasgow Blatchford Score\* ≥ 6)
  • Signs, symptoms or history of liver cirrhosis or liver failure
  • Signs, symptoms or history of decompensated heart failure or congestive heart failure
  • Presumed Pregnant, trying to conceive or breastfeeding
  • Known history of gastric cancer
  • Known history of gastric or esophageal varices
  • GI surgery within the last 6 months
  • Prior enrollment in the CHEER Study
  • Prisoner or Ward of State
  • Trouble swallowing, suspected bowel obstruction or perforation, per treating clinician
  • Past UGI tract surgery (e.g., Bilroth I or II, esophagectomy, gastrectomy, bariatric procedure) that changes Gastrointestinal anatomy
  • Known history of gastroparesis, esophageal stricture or Crohn's disease
  • Altered mental status that limits the ability to swallow a capsule
  • Expected to have Magnetic Resonance Imaging (MRI) examination within 7 days
  • Consumed medications within the past 12 hours that may coat the upper GI tract such as antacids or sucralfate or Maalox and potentially limits capsule visualization
  • Patient either refuses or is unable to get traditional EGD
  • Patient does not have reliable contact information - no phone, no permanent address
  • Patient refuses
  • Unable to provide written consent
  • Non-English speaker
  • Suspected middle or lower GI bleeding
  • Treating ED Physician is not amenable to admission or discharge based on randomization or Video Capsule Endoscopy results. \* As a modification, the GBS Score modified from the traditional GBS score to reduce the Hemoglobin cut-off for 6 points from 10g/dL to 9 g/dL (see Appendix B, CHEER 4; patient screening)

Key Trial Info

Start Date :

April 17 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 7 2020

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT03458000

Start Date

April 17 2018

End Date

September 7 2020

Last Update

June 1 2023

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

George Washington University

Washington D.C., District of Columbia, United States, 20037

2

Duke University School of Medicine

Durham, North Carolina, United States, 27710

3

Temple University

Philadelphia, Pennsylvania, United States, 19140